Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, Cairncross G
Department of Oncology, University of Western Ontario, London, Canada.
J Clin Oncol. 1997 Apr;15(4):1294-301. doi: 10.1200/JCO.1997.15.4.1294.
To review the outcomes of patients with low-grade glioma diagnosed by modern imaging and treated at a center where postponing radiotherapy was common practice.
We reviewed the records of patients (age > or = 18 years) with pathologically confirmed supratentorial low-grade fibrillary astrocytoma, oligodendroglioma, and mixed glioma treated at a regional cancer center in Canada between 1979 and 1995.
Median survival for the entire group (N = 167; mean age 40.6 years) was 10.5 years with 5- and 10-year survival rates of 72% and 50%, respectively. Median progression-free survival was 4.9 years with 5- and 10-year progression-free rates of 50% and 12%, respectively. Overall and progression-free survivals were longer for patients with an oligodendroglioma or mixed glioma than with astrocytoma (median 13 v 7.5 years, P = .003; progression-free 5.6 v 4.4 years, p = .054). Age at diagnosis < or = 40 years, seizures at presentation, minimal residual tumor after surgery, Karnofsky performance status > or = 70, and oligodendroglioma or mixed glioma pathology were associated with significantly longer median survival on univariate and multivariate analyses. Radiotherapy deferred until tumor progression (v immediate radiotherapy) was associated with longer survival on univariate analysis, but an imbalance in other variables accounted for this advantage such that timing of radiotherapy was not an independent (favorable or adverse) prognostic factor on multivariate analysis.
Patients with low-grade glioma diagnosed by modern imaging can be expected to live a long time; timing of radiotherapy may be a less important determinant of survival than nontreatment variables and residual tumor bulk.
回顾经现代影像学诊断并在一个常采用推迟放疗做法的中心接受治疗的低级别胶质瘤患者的治疗结果。
我们回顾了1979年至1995年期间在加拿大一家地区癌症中心接受治疗的年龄≥18岁、经病理证实为幕上低级别纤维型星形细胞瘤、少突胶质细胞瘤和混合性胶质瘤患者的记录。
整个队列(N = 167;平均年龄40.6岁)的中位生存期为10.5年,5年和10年生存率分别为72%和50%。中位无进展生存期为4.9年,5年和10年无进展率分别为50%和12%。少突胶质细胞瘤或混合性胶质瘤患者的总生存期和无进展生存期长于星形细胞瘤患者(中位生存期分别为13年和7.5年,P = 0.003;无进展生存期分别为5.6年和4.4年,p = 0.054)。单因素和多因素分析显示,诊断时年龄≤40岁、就诊时癫痫发作、手术后残留肿瘤最小、卡氏评分≥70以及少突胶质细胞瘤或混合性胶质瘤病理与显著更长的中位生存期相关。单因素分析显示,放疗推迟至肿瘤进展(与立即放疗相比)与更长的生存期相关,但其他变量的不平衡解释了这一优势,因此在多因素分析中,放疗时机不是一个独立的(有利或不利)预后因素。
经现代影像学诊断的低级别胶质瘤患者有望长期生存;放疗时机可能不如非治疗变量和残留肿瘤体积对生存的影响重要。